The Health Ministry has agreed to grant additional indication approval for the product Evusheld 100 milligrammes per millimetre (mg/ml) Solution for Injection (Tixagevimab 100 mg/ml and Cilgavimab 100 mg/ml) manufactured by Astrazeneca AB of Sweden.

Health director-general Dr Noor Hisham Abdullah said the approval was made at the 383rd Drug Control Authority (DCA) meeting which convened yesterday (April 6).

Earlier, the 372nd meeting agreed to grant conditional registration approval for the same product..